NasdaqCM - Delayed Quote USD

Capricor Therapeutics, Inc. (CAPR)

Compare
21.60 +2.02 (+10.32%)
At close: October 15 at 4:00 PM EDT
21.60 0.00 (0.00%)
Pre-Market: 7:08 AM EDT
Loading Chart for CAPR
DELL
  • Previous Close 19.58
  • Open 19.30
  • Bid 21.44 x 500
  • Ask 21.77 x 500
  • Day's Range 18.92 - 23.40
  • 52 Week Range 2.68 - 23.40
  • Volume 3,670,608
  • Avg. Volume 2,665,146
  • Market Cap (intraday) 763.288M
  • Beta (5Y Monthly) 4.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.89
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.00

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

www.capricor.com

101

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CAPR

View More

Performance Overview: CAPR

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CAPR
341.72%
S&P 500
21.92%

1-Year Return

CAPR
655.24%
S&P 500
34.37%

3-Year Return

CAPR
419.23%
S&P 500
31.03%

5-Year Return

CAPR
740.47%
S&P 500
96.05%

Compare To: CAPR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CAPR

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    691.91M

  • Enterprise Value

    664.28M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    23.79

  • Price/Book (mrq)

    66.30

  • Enterprise Value/Revenue

    27.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -102.93%

  • Return on Assets (ttm)

    -44.49%

  • Return on Equity (ttm)

    -392.69%

  • Revenue (ttm)

    27.15M

  • Net Income Avi to Common (ttm)

    -27.95M

  • Diluted EPS (ttm)

    -0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.46M

  • Total Debt/Equity (mrq)

    15.97%

  • Levered Free Cash Flow (ttm)

    -23.55M

Research Analysis: CAPR

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 3.97M
Earnings -11M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

25.00
39.00 Average
21.60 Current
77.00 High
 

Company Insights: CAPR

People Also Watch